NCT05245006 2026-03-17
PET Imaging Study of 89Zr-DFO-YS5 in Men With Prostate Cancer
University of California, San Francisco
Phase 1 Active not recruiting
Clinical Trials
252 trialsNCT07090148 2026-03-11
Trial of pTVG-HP+Nivo+Targeted Ablation of Resistant Lesions in Non-Castrate RecurrentOMPC
University of Wisconsin, Madison
Phase 1 Recruiting
NCT03674814 2026-03-04
Study of Drug 1 (Enzalutamide) Plus Drug 2 (Relacorilant) for Patients With Prostate Cancer
University of Chicago
Phase 1 Active not recruiting
NCT05617885 2026-02-27
Neo-DAB: Darolutamide and Abemaciclib in Prostate Cancer
Dana-Farber Cancer Institute
Phase 1 Active not recruiting
NCT02353819 2026-02-23
Stereotactic Ablative Radiotherapy (SABR) of Pelvis and Prostate Targets For High Risk Prostate Cancer
University of Texas Southwestern Medical Center
Phase 1 Active not recruiting
NCT03089203 2026-02-23
CART-PSMA-TGFβRDN Cells for Castrate-Resistant Prostate Cancer
University of Pennsylvania
Phase 1 Active not recruiting
NCT06305598 2026-02-19
Bipolar Androgen Therapy to Restore Sensitivity to Androgen Deprivation Therapy for Patients With Metastatic Castration Resistant Prostate Cancer
Roswell Park Cancer Institute
Phase 1 Recruiting
NCT02776436 2026-02-17
REDEX
Leiden University Medical Center
Phase 1 Completed
NCT06631521 2026-02-05
Neoadjuvant Darolutamide and Relugolix Combination Preceding Radical Prostatectomy for Prostate Cancer
AdventHealth
Phase 1 Recruiting
NCT07219147 2026-01-28
177^Lu-PSMA-617 in Combination With Sipuleucel-T for the Treatment of Metastatic Castration-Resistant Prostate Cancer
City of Hope Medical Center
Phase 1 Recruiting
NCT01140373 2026-01-15
Adoptive Transfer of Autologous T Cells Targeted to Prostate Specific Membrane Antigen (PSMA) for the Treatment of Castrate Metastatic Prostate Cancer (CMPC)
Memorial Sloan Kettering Cancer Center
Phase 1 Active not recruiting
NCT05010200 2026-01-07
PGV-Prostate
Icahn School of Medicine at Mount Sinai
Phase 1 Active not recruiting
NCT07316686 2026-01-05
Lutécio
Instituto do Cancer do Estado de São Paulo
Phase 1 Not yet recruiting
NCT07145177 2025-12-18
177Lu-PSMA-617 With Liver Directed Therapy in Metastatic Castration Resistant Prostate Cancer
University of California, San Francisco
Phase 1 Not yet recruiting
NCT05162573 2025-12-10
PROQURE-1
The Netherlands Cancer Institute
Phase 1 Completed
NCT07271017 2025-12-08
Robot-Assisted Prostate Biopsy With a Novel Ultrasound Probe
Johns Hopkins University
Phase 1 Recruiting
NCT07054346 2025-12-01
LUTACT
University of California, San Francisco
Phase 1 Recruiting
NCT01923506 2025-11-26
Stereotactic Body Radiation Therapy in Treating Patients With Prostate Cancer After Undergoing Surgery
City of Hope Medical Center
Phase 1 Active not recruiting
NCT02023463 2025-11-25
Enzalutamide, Radiation Therapy and Hormone Therapy in Treating Patients With Intermediate or High-Risk Prostate Cancer
Thomas Jefferson University
Phase 1 Active not recruiting
NCT04388852 2025-11-21
DS3201 and Ipilimumab for the Treatment of Metastatic Prostate, Urothelial and Renal Cell Cancers
M.D. Anderson Cancer Center
Phase 1 Active not recruiting
NCT05805371 2025-11-19
PSCA-Targeting CAR-T Cells Plus or Minus Radiation for the Treatment of Patients With PSCA+ Metastatic Castration-Resistant Prostate Cancer
City of Hope Medical Center
Phase 1 Recruiting
NCT03582475 2025-11-12
Pembrolizumab With Combination Chemotherapy in Treating Participants With Locally Advanced or Metastatic Small Cell/Neuroendocrine Cancers of Urothelium or Prostate
Jonsson Comprehensive Cancer Center
Phase 1 Active not recruiting
NCT05037500 2025-11-12
Decitabine/Cedazuridine and Enzalutamide for the Treatment of Metastatic Castrate Resistant Prostate Cancer
Roswell Park Cancer Institute
Phase 1 Terminated
NCT05079698 2025-11-10
A Study of Stereotactic Body Radiotherapy and 177Lu-PSMA-617 for the Treatment of Prostate Cancer
Memorial Sloan Kettering Cancer Center
Phase 1 Recruiting
NCT06062745 2025-11-05
Pilot Study for Detection of PSMA-Low CRPC-NE Tumors With Fluciclovine PET/CT
Brigham and Women's Hospital
Phase 1 Recruiting
NCT04167969 2025-10-14
The Use of Nanoparticles to Guide the Surgical Treatment of Prostate Cancer
Memorial Sloan Kettering Cancer Center
Phase 1 Recruiting
NCT03737370 2025-10-07
Fractionated Docetaxel and Radium 223 in Metastatic Castration-Resistant Prostate Cancer
Tufts Medical Center
Phase 1 Completed
NCT04887935 2025-10-01
Neoadjuvant SGLT2 Inhibition in Localized Prostate Cancer
Washington University School of Medicine
Phase 1 Recruiting
NCT03269422 2025-09-30
Radiotherapy to the Prostate and Dominant Intra-Prostatic Lesion (DIL)
Memorial Sloan Kettering Cancer Center
Phase 1 Active not recruiting
NCT05733351 2025-09-15
Vudalimab (XmAb20717) in Combination With Standard of Care Treatment in Patients With Metastatic Castration Sensitive Prostate Cancer
Emory University
Phase 1 Terminated
NCT01655836 2025-09-11
High-Dose Rate Brachytherapy and Stereotactic Body Radiation Therapy in Treating Patients With Prostate Cancer
Thomas Jefferson University
Phase 1 Active not recruiting
NCT05375539 2025-09-10
AGN-CognI.Q Acute Dose Safety and Pharmacokinetics Dose-Response in Prostate Cancer Patients
Milton S. Hershey Medical Center
Phase 1 Completed
NCT07100847 2025-09-09
Periprostatic Neurolysis in Prostate Cancer
University of Texas Southwestern Medical Center
Phase 1 Recruiting
NCT06168487 2025-08-21
Telmisartan in Prostate Cancer
Dartmouth-Hitchcock Medical Center
Phase 1 Recruiting
NCT00977457 2025-08-19
Genetic Testing in Predicting Biomarkers of Recurrence in Patients With Prostate Cancer Undergoing Surgery
City of Hope Medical Center
Phase 1 Active not recruiting
NCT07118176 2025-08-12
Determining the Biodistribution of an Imaging Tracer (68Ga-FAPi-46) in Patients With Solid Tumors or Hematologic Cancers
Jonsson Comprehensive Cancer Center
Phase 1 Recruiting
NCT06441994 2025-07-31
Alpha-PS1
Osaka University
Phase 1 Recruiting
NCT07090369 2025-07-29
LumOnate
Peter MacCallum Cancer Centre, Australia
Phase 1 Not yet recruiting
NCT06942104 2025-07-18
Imaging of Solid Tumors Using 18F-TRX
University of California, San Francisco
Phase 1 Recruiting
NCT04457232 2025-07-15
FAPI PET Prost
Jonsson Comprehensive Cancer Center
Phase 1 Active not recruiting
NCT06303713 2025-06-05
LuCarbo - a Study of 177Lu-PSMA-617 Plus Carboplatin in Metastatic Castrate-resistant Prostate Cancer
Dana-Farber Cancer Institute
Phase 1 Recruiting
NCT00911118 2025-06-03
Dose Escalation Study Using Ultra-Hypofractionated, Image-Guided, Intensity-Modulated Radiotherapy in Prostate Cancer
Memorial Sloan Kettering Cancer Center
Phase 1 Active not recruiting
NCT04927663 2025-05-20
11C-YJH08 PET Imaging for Detection of Glucocorticoid Receptor Expression
University of California, San Francisco
Phase 1 Terminated
NCT00328614 2025-05-16
Samarium-153 With Neoadjuvant Hormonal and Radiation Therapy for Locally Advanced Prostate Cancer
Thomas Jefferson University
Phase 1 Completed
NCT01420250 2025-05-15
Cabazitaxel With Radiation and Hormone Therapy for Prostate Cancer
Thomas Jefferson University
Phase 1 Completed
NCT06673329 2025-05-14
Brodalumab in the Treatment of Immune-Related Adverse Events
Columbia University
Phase 1 Recruiting
NCT03300505 2025-05-13
ARRx in Combination With Enzalutamide in Metastatic Castration Resistant Prostate Cancer
University of Michigan Rogel Cancer Center
Phase 1 Terminated
NCT05398302 2025-05-13
Image-Guided Biopsies to Identify Mechanisms of Resistance in Patients With Metastatic Castration Resistant Prostate Cancer Treated With 177Lu-PSMA Radioligand Therapy
Jonsson Comprehensive Cancer Center
Phase 1 Recruiting
NCT04186585 2025-05-09
Recommended Dose Estimation of BP-C2
Meddoc
Phase 1 Recruiting
NCT01341288 2025-05-02
EUCLIDIAN
Thomas Jefferson University
Phase 1 Terminated